CytoMed Gets 180 Days to Address Nasdaq Bid-Price Shortfall
The company has until April 5, 2027, to meet Nasdaq’s minimum bid-price rule, with its listing unaffected for now.
Key takeaways
- Nasdaq said CytoMed’s closing bid price was below $1 for 30 consecutive business days.
- CytoMed has until April 5, 2027, to regain compliance; the notice does not affect its listing or trading.
CytoMed Therapeutics received a Nasdaq notice after its ordinary shares closed below the exchange’s $1 minimum bid price for 30 consecutive business days. The notice has no current effect on the shares’ listing or trading.
The company has until April 5, 2027, to regain compliance. Nasdaq will consider the requirement met if the closing bid price is at least $1 for 10 consecutive business days during that period.
If CytoMed does not meet the threshold by the deadline, it may qualify for another 180 days, subject to Nasdaq staff review and other listing requirements. The company said it may use a reverse stock split to address the deficiency and intends to take reasonable measures to regain compliance.
This article was produced with the help of AI technology. Source: Yahoo Finance
